Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1984 1
1987 1
1992 1
1996 1
1997 1
1998 1
2002 1
2006 2
2007 1
2008 1
2010 2
2011 3
2014 1
2015 1
2017 2
2019 1
2022 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3anti-GD2 bispecific antibody armed T cells.
Yankelevich M, Thakur A, Modak S, Chu R, Taub J, Martin A, Schalk D, Schienshang A, Whitaker S, Rea K, Lee DW, Liu Q, Shields AF, Cheung NV, Lum LG. Yankelevich M, et al. J Immunother Cancer. 2024 Mar 21;12(3):e008744. doi: 10.1136/jitc-2023-008744. J Immunother Cancer. 2024. PMID: 38519053 Free PMC article. Clinical Trial.
BACKGROUND: The survival benefit observed in children with neuroblastoma (NB) and minimal residual disease who received treatment with anti-GD2 monoclonal antibodies prompted our investigation into the safety and potential clinical benefits of anti-CD3anti-GD2 bispecific a …
BACKGROUND: The survival benefit observed in children with neuroblastoma (NB) and minimal residual disease who received treatment wit …
Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives.
Cooper JP, Reynolds CP, Cho H, Kang MH. Cooper JP, et al. Exp Biol Med (Maywood). 2017 Jun;242(11):1178-1184. doi: 10.1177/1535370217706952. Epub 2017 Apr 21. Exp Biol Med (Maywood). 2017. PMID: 28429653 Free PMC article. Review.
ILE 4-HPR administered as five-day continuous infusion achieved over 50 mol/L at MTD with minimal systemic toxicities; multiple complete and partial responses were observed in peripheral T cell lymphomas. The LXS oral powder 4-HPR formulation increased plasma levels approx …
ILE 4-HPR administered as five-day continuous infusion achieved over 50 mol/L at MTD with minimal systemic toxicities; multiple complete and …
Efficacy of proton therapy in children with high-risk and locally recurrent neuroblastoma.
Bagley AF, Grosshans DR, Philip NV, Foster J, McAleer MF, McGovern SL, Lassen-Ramshad Y, Mahajan A, Paulino AC. Bagley AF, et al. Pediatr Blood Cancer. 2019 Aug;66(8):e27786. doi: 10.1002/pbc.27786. Epub 2019 May 2. Pediatr Blood Cancer. 2019. PMID: 31050179 Free PMC article.
METHODS AND MATERIALS: Eighteen patients with high-risk (n = 16) and locally recurrent neuroblastoma (n = 2) were treated with curative intent and received proton therapy to the primary site and up to three post-induction MIBG-avid metastatic sites. ...RESULTS: With …
METHODS AND MATERIALS: Eighteen patients with high-risk (n = 16) and locally recurrent neuroblastoma (n = 2) were treated with …
Allele-specific expression reveals genes with recurrent cis-regulatory alterations in high-risk neuroblastoma.
Sen A, Huo Y, Elster J, Zage PE, McVicker G. Sen A, et al. Genome Biol. 2022 Mar 4;23(1):71. doi: 10.1186/s13059-022-02640-y. Genome Biol. 2022. PMID: 35246212 Free PMC article.
Here, we analyze allele-specific expression in 96 high-risk neuroblastoma tumors to discover genes impacted by cis-acting mutations that alter dosage. RESULTS: We identify 1043 genes with recurrent, neuroblastoma-specific allele-specific expression. While most of th …
Here, we analyze allele-specific expression in 96 high-risk neuroblastoma tumors to discover genes impacted by cis-acting mutations that alt …
Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project.
London WB, Castel V, Monclair T, Ambros PF, Pearson AD, Cohn SL, Berthold F, Nakagawara A, Ladenstein RL, Iehara T, Matthay KK. London WB, et al. J Clin Oncol. 2011 Aug 20;29(24):3286-92. doi: 10.1200/JCO.2010.34.3392. Epub 2011 Jul 18. J Clin Oncol. 2011. PMID: 21768459 Free PMC article.
Our aim was to determine which factors were significantly predictive of postrelapse overall survival (OS) in patients with recurrent neuroblastoma--particularly whether time from diagnosis to first relapse (TTFR) was a significant predictor of OS. ...T …
Our aim was to determine which factors were significantly predictive of postrelapse overall survival (OS) in patients with recurre …
Outcome of children with relapsed high-risk neuroblastoma in Japan and analysis of the role of allogeneic hematopoietic stem cell transplantation.
Hara J, Nitani C, Shichino H, Kuroda T, Hishiki T, Soejima T, Mori T, Matsumoto K, Sasahara Y, Iehara T, Miyamura T, Kosaka Y, Takimoto T, Nakagawara A, Tajiri T; Japan Children’s Cancer Group (JCCG) Neuroblastoma Committee (JNBSG). Hara J, et al. Jpn J Clin Oncol. 2022 May 5;52(5):486-492. doi: 10.1093/jjco/hyac007. Jpn J Clin Oncol. 2022. PMID: 35137156
This retrospective study aimed to investigate the prognosis of recurrent neuroblastoma in Japan and explore the effectiveness of allogeneic hematopoietic stem cell transplantation. ...The duration of initial remission ( 18 months) and implementation of allogeneic he …
This retrospective study aimed to investigate the prognosis of recurrent neuroblastoma in Japan and explore the effectiveness …
Recurrent neuroblastoma: the role of CT and alternative imaging tests.
Stark DD, Brasch RC, Moss AA, deLorimier AA, Albin AR, London DA, Gooding CA. Stark DD, et al. Radiology. 1983 Jul;148(1):107-12. doi: 10.1148/radiology.148.1.6856818. Radiology. 1983. PMID: 6856818
CT was accurate and clinically useful both for assessing tumor response to therapy and for predicting findings at "second look" surgery (accuracy, 94%). CT is relatively cost effective by substituting for a more expensive but less accurate combination of competitive imagin …
CT was accurate and clinically useful both for assessing tumor response to therapy and for predicting findings at "second look" surge …
A phase 2 trial of all-trans-retinoic acid in combination with interferon-alpha2a in children with recurrent neuroblastoma or Wilms tumor: A Pediatric Oncology Branch, NCI and Children's Oncology Group Study.
Adamson PC, Matthay KK, O'Brien M, Reaman GH, Sato JK, Balis FM. Adamson PC, et al. Pediatr Blood Cancer. 2007 Oct 15;49(5):661-5. doi: 10.1002/pbc.21011. Pediatr Blood Cancer. 2007. PMID: 16900483 Clinical Trial.
Overall, the combination was well tolerated, with headache being the most common toxicity observed. There were no complete or partial responses. The median number of cycles administered was 1 (range 1-9). ...
Overall, the combination was well tolerated, with headache being the most common toxicity observed. There were no complete or partial …
Assessment of Organ Dosimetry for Planning Repeat Treatments of High-Dose 131I-MIBG Therapy: 123I-MIBG Versus Posttherapy 131I-MIBG Imaging.
Pandit-Taskar N, Zanzonico P, Hilden P, Ostrovnaya I, Carrasquillo JA, Modak S. Pandit-Taskar N, et al. Clin Nucl Med. 2017 Oct;42(10):741-748. doi: 10.1097/RLU.0000000000001752. Clin Nucl Med. 2017. PMID: 28759518 Free PMC article. Clinical Trial.
METHODS: In a prospective study, 33 patients with high-risk refractory or recurrent neuroblastoma were treated with high-dose I-MIBG. Organ dosimetry was estimated from the first I-MIBG posttherapy imaging and from subsequent I-MIBG imaging prior to the planned seco …
METHODS: In a prospective study, 33 patients with high-risk refractory or recurrent neuroblastoma were treated with high-dose …
Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma.
Fang H, Harned TM, Kalous O, Maldonado V, DeClerck YA, Reynolds CP. Fang H, et al. Clin Cancer Res. 2011 Nov 15;17(22):7093-104. doi: 10.1158/1078-0432.CCR-11-0578. Epub 2011 Sep 20. Clin Cancer Res. 2011. PMID: 21933888 Free PMC article.
The effect of these agents alone and in combination on mitochondrial membrane depolarization and apoptosis (by flow cytometry), cytochrome c release, caspases, Bax-alpha, t-Bid, and Bak activation, and subcutaneous xenografts in nu/nu mice was also determined. RESULTS: Multilog s …
The effect of these agents alone and in combination on mitochondrial membrane depolarization and apoptosis (by flow cytometry), cytochrome c …
24 results